Livongo Health (NASDAQ:LVGO) and Emmaus Life Sciences (NASDAQ:EMMA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends.
Insider & Institutional Ownership
0.1% of Emmaus Life Sciences shares are owned by institutional investors. 36.9% of Emmaus Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a summary of current recommendations for Livongo Health and Emmaus Life Sciences, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Emmaus Life Sciences||0||0||0||0||N/A|
Livongo Health presently has a consensus price target of $44.20, suggesting a potential upside of 27.60%. Given Livongo Health’s higher possible upside, analysts clearly believe Livongo Health is more favorable than Emmaus Life Sciences.
This table compares Livongo Health and Emmaus Life Sciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Emmaus Life Sciences||-489.28%||-511.05%||-209.39%|
Valuation and Earnings
This table compares Livongo Health and Emmaus Life Sciences’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Emmaus Life Sciences||$1.32 million||116.88||-$9.59 million||($11.16)||-0.29|
Livongo Health has higher earnings, but lower revenue than Emmaus Life Sciences.
Livongo Health beats Emmaus Life Sciences on 5 of the 8 factors compared between the two stocks.
Livongo Health Company Profile
Livongo Health, Inc. provides an integrated suite of solutions for the healthcare industry in North America. It solutions promote health behavior change based on real-time data capture supported by intuitive devices and insights driven by data science. The company offers a platform that provides cellular-connected devices, supplies, informed coaching, data science-enabled insights, and facilitates access to medications. Its products include Livongo for Diabetes, Livongo for Hypertension, Livongo for Prediabetes and Weight Management, and Livongo for Behavioral Health by myStrength. The company was formerly known as EosHealth, Inc. and changed its name to Livongo Health, Inc. in 2014. Livongo Health, Inc. was incorporated in 2008 and is headquartered in Mountain View, California.
Emmaus Life Sciences Company Profile
Emmaus Life Sciences, Inc. engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older; NutreStore L-glutamine powder; and AminoPure, a nutritional supplement. The company also develops therapeutic products based on cell sheet technology for the treatment of corneal diseases. In addition, it focuses on developing pharmaceutical-grade L-glutamine oral powder for diverticulosis. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
Receive News & Ratings for Livongo Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Livongo Health and related companies with MarketBeat.com's FREE daily email newsletter.